Sequence: RKKRRQRRRHRRKKR
| Experiment Id | EXP001415 |
|---|---|
| Paper | Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silen |
| Peptide | dTAT (double TAT) |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | dTAT 40 mg/mL formulation; injected 200 µL IV (mouse dose depends on body weight; fixed formulation per group) |
| Rna Concentration | 38.5 µM or 77 µM siRNA in injection formulation (200 µL IV); tissues analyzed at 48 h |
| Mixing Ratio | dTAT + GAPDH siRNA + CaCl2 (final ~70 mM) + glucose (2%) |
| Formulation Format | Calcium-condensed CPP/siRNA nanoparticles (IV) |
| Formulation Components | dTAT + GAPDH siRNA + CaCl2 + glucose |
| Size Nm | 251.00 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | Balb/C mice (male; 8–12 weeks); tissues: brain, liver, kidney, lung, muscle, stomach |
| Administration Route | Intravenous (tail vein) |
| Output Type | In vivo mRNA knockdown (GAPDH mRNA by qRT-PCR) and siRNA biodistribution (qRT-PCR of siRNA) |
| Output Value | |
| Output Units | |
| Output Notes | Significant GAPDH mRNA knockdown observed especially in lung (both doses), and at higher dose also in muscle and stomach; some knockdown in liver reported. siRNA accumulation highest in lung; dose-dependent. |
| Toxicity Notes | Dose-escalation arm suggests high tolerability of dTAT complexes; no major acute toxicity reported for knockdown/biodistribution dosing. |
| Curation Notes |